SanofiMIL:1SAN -0.16%72 Net Margin % is 7.89% as of Dec. 2025, which is 46% below its 10-year median of 14.73. GuruFocus rates MIL:1SAN with a GF Score™ of 72/100 and a GF Value™ of €106.79 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 956 Drug Manufacturers companies, Sanofi ranks better than 82.11% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Sanofi's Net Income for the
six
months ended in Dec. 2025 was €2,001 Mil. Sanofi's Revenue for the
six
months ended in Dec. 2025 was €25,375 Mil. Therefore, Sanofi's net margin for the quarter that ended in Dec. 2025 was 7.89%.
The historical rank and industry rank for Sanofi's Net Margin % or its related term are showing as below:
MIL:1SAN'
s Net Margin % Range Over the Past 10 Years
Min: 7.32 Med: 14.73 Max: 32.9
Current: 16.72
MIL:1SAN's Net Margin % is ranked better than 82.11% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs MIL:1SAN: 16.72
Sanofi (MIL:1SAN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sanofi Net Margin % Related Terms
Sanofi Net Margin % Historical Data
* Premium members only.
The historical data trend for Sanofi's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1SAN vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Sanofi's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sanofi's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi (MIL:1SAN) has a Net Margin % of 7.89% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Sanofi and its competitors. This is 46% below median its historical median of 14.73. Over the past decade, Sanofi's Net Margin % has ranged from 7.32 to 32.90. According to the industry distribution chart, Sanofi ranks #171 out of 956 companies in the Drug Manufacturers industry, placing it in the top 17.9%.
Is Sanofi's Net Margin % too high?
Sanofi's current Net Margin % of 7.89% is 46% below median its 10-year median of 14.73. Over the past 10 years, this metric has ranged from a low of 7.32 to a high of 32.90. The Drug Manufacturers industry median Net Margin % is 5.56. Sanofi's value of 7.89% is 41.9% above this industry median. Based on the distribution chart, Sanofi ranks #171 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi ranks #171 out of 956 companies for Net Margin %. This places Sanofi in the top 18% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Sanofi's value of 7.89% is 41.9% above this benchmark. Historically, Sanofi's own Net Margin % has ranged from 7.32 to 32.90 over the past decade. While the company's 10-year median is 14.73 vs. the industry median of 5.56, Sanofi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi's current Net Margin % of 7.89% is 41.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sanofi and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi's current Net Margin % is 7.89%, which is 46% below median its own 10-year median of 14.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (MIL:1SAN) is currently considered Possible Value Trap. The stock's GF Value™ is €106.79, compared to a current price of €73.43 — trading 31.2% below its estimated fair value. The current Net Margin % is 7.89%, which is 46% below median its 10-year median of 14.73 and 41.9% above the Drug Manufacturers industry median of 5.56. Sanofi's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sanofi (MIL:1SAN), the current Net Margin % is 7.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi (MIL:1SAN) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi stock appears to be undervalued.
The current stock price of €73.43 is trading 31.2% below its estimated GF Value™ of €106.79.
GuruFocus considers Sanofi to be Possible Value Trap.
Key valuation signals for MIL:1SAN:
Net Margin %: 7.89% (46% below median its 10-year median of 14.73)
GF Value™: €106.79 vs. price of €73.43 (31.2% below fair value)
Industry Position: 41.9% above the Drug Manufacturers median (#171 of 956)
No single metric tells the full story. See the MIL:1SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
72GF Score
Get the complete analysis for MIL:1SAN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1SAN has been successfully added to your 
